吉非替尼治疗34例晚期非小细胞肺癌的临床观察  

Clinical observation of Gefitinib for 34 patients with advanced non-small cell lung cancer

作　　者：窦洪光 赵树平[1] 李雪红[1] 

机构地区：[1]黑龙江省农垦总医院,黑龙江哈尔滨150088

出　　处：《中国医药导报》2010年第18期72-72,74,共2页China Medical Herald

摘　　要：目的:探讨晚期非小细胞肺癌(NSCLC)患者应用吉非替尼治疗的效果及毒副作用。方法:34例经放化疗失败的非小细胞肺癌晚期患者,均发生远处转移。口服吉非替尼250mg/次,每天1次,服药中位时间为4个月。结果:34例晚期NSCLC患者,无一例完全缓解(CR),19例部分缓解(PR),10例稳定(SD),5例进展(PD),全组有效率(CR+PR)为55.9%,临床获益率(CR+PR+SD)为85.3%。中位生存期5.6个月,1年生存率为47.1%(16/34)。结论:吉非替尼治疗晚期NSCLC的疗效较好,毒副作用较轻,可以耐受。Objective：To explore the efficacy and toxicity of Gefitinib for the patients with advanced non-small cell lung cancer（NSCLC）.Methods：34 patients with advanced NSCLC were unsuitable for chemoradio therapy.Gefitinib was administered orally at 250 mg,once a day until cancer progressed or serve toxicities occurred.The median time for administered of Gefitinib was 4 months.Results：Among the 34 NSCLC,no complete response（CR） and 19 partial response（PR）,the objective response rate（CR＋PR） was 55.9%,and the disease control rate（CR＋PR＋SD） was 85.3%.The median survival time was 5.6 months,and one year survival rate was 47.1%（16/34）.Conclusion：Gefitinib in the treatment of patients with advanced NSCLC has better efficacy and well-tolerated toxicity.

关 键 词：非小细胞肺癌 吉非替尼 靶向治疗 表皮生长因子受体 

分 类 号：R734.2[医药卫生—肿瘤]